Thrombolytic Science International   Report issue

For profit Phase 2
Founded: Cambridge MA United States (2006)

Organization Overview

First Clinical Trial
2019
NCT04256473
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

DUMAS is sponsored by an unrestricted grant from Thrombolytic Science International, paid to the institution.

Active Ingredients

Drugs in Phase 2 Trials (2)

alteplase (Activase) (1 trial)

mutant pro-urokinase (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Infarction (Phase 2)

Ischemia (Phase 2)

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2